HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel
about
Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early TreatmentHIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trialEvaluating a Brief, Video-Based Sexual Risk Reduction Intervention and Assessment Reactivity with STI Clinic Patients: Results from a Randomized Controlled Trial.How can we better identify early HIV infections?Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions.The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV PreventionPre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges.Advancing the strategic use of HIV operations research to strengthen local policies and programmes: the Research to Prevention Project.Development and validation of the San Diego Early Test Score to predict acute and early HIV infection risk in men who have sex with men.Repeat HIV-testing is associated with an increase in behavioral risk among men who have sex with men: a cohort study.Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in HIV-Infected Patients in MozambiqueMeta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment RegimensAwareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementationThe preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA.Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African WomenA practical online tool to estimate antiretroviral coverage for HIV infected and susceptible populations needed to reduce local HIV epidemics.Evidence and the Politics of Deimplementation: The Rise and Decline of the "Counseling and Testing" Paradigm for HIV Prevention at the US Centers for Disease Control and Prevention.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA PanelTowards an integrated primary and secondary HIV prevention continuum for the United States: a cyclical process model.Realizing the potential of treatment as prevention: global ART policy and treatment coverage.Primary resistance to integrase strand-transfer inhibitors in Europe.Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.Retention in Care Services Reported by HIV Care Providers in the United States, 2013 to 2014The Usefulness of Individual-Level HIV Surveillance Data to Initiate Statewide HIV Partner Services: Experiences From Hawaii and New Mexico.What is the benefit of the biomedical and behavioral interventions in preventing HIV transmission?New challenges in therapeutic vaccines against HIV infection.Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.HIV Prevention: Opportunities and Challenges.Human Immunodeficiency Virus, Other Sexually Transmitted Infections, and Sexual and Reproductive Health in Lesbian, Gay, Bisexual, Transgender Youth.Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012-2013.The impact of HIV infection and socioeconomic factors on the incidence of gonorrhea: A county-level, US-wide analysis.Implementation of HIV treatment as prevention strategy in 17 Canadian sites: immediate and sustained outcomes from a 35-month Quality Improvement Collaborative.Male condom use, multiple sexual partners and HIV: a prospective case-control study in Kinshasa (DRC).A SWOT Analysis of the Updated National HIV/AIDS Strategy for the U.S., 2015-2020.Treatment outcomes among people living with HIV who are food insecure and prescribed antiretrovirals taken with food.Additional Indicators to Measure New HIV Diagnoses: A Response to Chow et alPrEP Implementation Science: State-of-the-Art and Research Agenda.
P2860
Q26778085-87795024-7988-4032-B069-25DE38096284Q33848307-74082777-3B4B-4265-B65C-9CB616332D50Q35667718-CD602C0A-8DEC-4AFB-980E-7D093196F672Q35814304-B00AF3A6-69AE-4A0C-A493-AA2771C8CBF9Q35817533-C0FAFCD8-D6CF-473E-9294-8F85CD9C4AB8Q35821208-77C36CA0-692C-4835-8B22-A8F4161E49E4Q35875706-DAE94ED8-DE9E-42D9-A202-333800946617Q35973353-19F13331-D4ED-43F0-A8F2-FEB62C5764D3Q35975619-EB721339-B695-4990-AB8C-DD4D5D9B07EFQ36131438-CC954645-6878-40C3-8495-8DF50D5F9955Q36167138-17EDCCCB-C891-400A-BB6A-3F5EB36FCD82Q36206941-AD054E1C-48B9-4A75-8E42-79636B3C96AEQ36296707-C8A43C6C-AA80-4700-96DC-50507C22768CQ36348296-28374C72-D819-45B5-AFAD-17472ECF07F2Q36443803-F7295428-1C11-42E0-A1A5-93206216F71BQ36591180-4EECF968-B59C-4035-A1DF-97E554B460D6Q37014243-B7B0C370-B612-46B8-826A-23E85A424827Q37034865-746A24E5-753B-458E-A37A-B856913B3153Q37087855-3C89C126-8882-4928-893D-4F3A6D427126Q37234729-4E880732-586B-4055-A5CF-F7C9AAB97B9FQ37423704-66B0B17C-F777-4975-A510-CE85E375550AQ38255369-93E1C13B-1E57-4D8C-A770-34FAF45B239BQ38424195-4ECE4580-DF92-44D4-B200-BE3BCA1AE1BDQ38594555-032FB074-F6A4-4110-976F-90163CF8B674Q38632655-C25F2A75-CCC2-4B0C-82CB-EA6A3501F06AQ38649299-34AB4A7F-ED29-45A4-9F6A-001715C5AA6CQ38656811-28C1A3D4-8A80-4A70-81B6-FE9C16A20631Q38692205-A01B7480-3CA6-4219-82B9-6E87809F97BDQ38737182-7A9B7A1B-B858-4C17-BEEE-24D17825F20AQ38861807-2FBE065B-4FFF-45E9-9D88-CE8B7E3C5B44Q38957187-AA9C3E90-2BBF-4C52-9AD2-7F3D368402FDQ39014130-BABDDD42-4444-4B7B-842C-5C1B93BE572BQ39643842-B65E5AB5-5DCA-4300-880C-E8A79466B94AQ40070635-02AA0BDE-52A9-45C1-8448-FEEEE3B86A37Q40299535-9375A8A5-1628-406F-840F-81A4D96211BEQ40449459-0D05FD98-A1C1-4F3B-97B7-1EE22DC19C95Q41000388-721BF45C-1BD0-407E-8ADE-693188FB3226Q41747332-34DEAD4F-FFD3-4DC3-B1F4-3CEB59BB2229Q42600017-A9311C6F-A893-4518-A81B-6965CC03CDBBQ43241737-51B89272-E58D-47C3-8601-20BC65F24AF4
P2860
HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@ast
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@en
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@nl
type
label
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@ast
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@en
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@nl
prefLabel
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@ast
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@en
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@nl
P2093
P50
P3181
P356
P1476
HIV prevention in clinical car ...... al Antiviral Society-USA Panel
@en
P2093
Beatriz Grinsztejn
Carlos del Rio
Constance A Benson
Darrell P Wheeler
David R Holtgrave
Francois Dabis
International Antiviral Society-USA Panel
Julio S G Montaner
Myron S Cohen
N Kumarasamy
P304
P3181
P356
10.1001/JAMA.2014.7999
P407
P577
2014-07-01T00:00:00Z